Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Beule, Dieter Dr. (2) Cakmak-Görür, Nese Dr. (1) Daniel, Peter Prof. Dr. (2) Dhamodaran, Arunraj (1) Kammertöns, Thomas Dr. (8) Kopp, Joachim Dr. (2) Leisegang, Matthias Prof. Dr. rer. nat. (3) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (4) Poncette, Lucia (1) Rhein, Simone Dr. (1) Siffrin, Volker (1) Uckert, Wolfgang Prof. Dr. (5) Willimsky, Gerald Dr. (3) (-) Blankenstein, Thomas Prof. Dr. (22) Bioinformatics and Omics Data Science (1) Biologie maligner Lymphome (14) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (22) Proteom Dynamik (1) Strukturbiologie Membran-assoziierter Prozesse (1) Systembiologie von Gen-regulatorischen Elementen (1) Translational Bioinformatics (2) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) (-) 2004 (8) 2005 (10) 2006 (1) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (3) (-) 2015 (3) 2016 (4) 2017 (6) 2018 (4) (-) 2019 (6) 2021 (4) 2022 (6) 2023 (5) 2024 (1) 22 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Molekulare Immunologie und Gentherapie 2004201120152019 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein 01. Januar 2004 / Nat Immunol A cancer immunosurveillance controversy Z.H. Qin T. Blankenstein 01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling 01. Januar 2004 / J Immunol Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18 T.H. Wu C.N. Pabin Z.H. Qin T. Blankenstein M. Philip J. Dignam K. Schreiber H. Schreiber 23. Januar 2004 The role of inflammation for tumour growth and tumour suppression T. Blankenstein 01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein 01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Nächste Seite Next › Letzte Seite Last »
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein
01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling
01. Januar 2004 / J Immunol Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18 T.H. Wu C.N. Pabin Z.H. Qin T. Blankenstein M. Philip J. Dignam K. Schreiber H. Schreiber
01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein
01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto